表紙
市場調查報告書
商品編碼
1029382

到 2030 年的庫欣綜合徵機會評估和預測

Cushing's Syndrome - Opportunity Assessment and Forecast to 2030

出版日期: | 出版商: GlobalData | 英文 55 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

庫欣綜合徵是一種由於體內一種叫做皮質醇的激素分泌過多而引起的疾病。皮質醇影響身體的所有組織和器官,這些影響統稱為 CS。該疾病主要由外源性給予糖皮質激素引起。內源性 CS 可由在身體其他部位產生過量皮質醇的腎上腺腫瘤引起,以及不依賴 ACTH 的 CS 或分泌 ACTH 的腦垂體腫瘤刺激腎上腺。它是由產生過量的皮質醇 (CD) 引起的。 )。

本報告涵蓋 2mm(美國和德國),並基於 Excel 提供了到 2030 年庫欣綜合徵市場的預測模型。

本報告探討了庫欣綜合徵市場,並概述了該疾病、治療方法、市場未滿足的需求、藥物管道趨勢和前景。

目錄

目錄

第 1 章執行摘要

  • 執行摘要

第2章疾病概述

  • 庫欣綜合徵概述

第2章:2庫欣綜合徵的SWOT分析

  • 庫欣綜合徵的分類

第 3 章流行病學

  • 確診 CS 病例:2020-2030
  • 2020 年按特定類型診斷的 CS 病例
  • 資料來源和研究方法
  • 庫欣綜合徵可治療人群

第 4 章當前的治療方案

  • 治療範式
  • 商業產品
  • 產品簡介:Corcept Therapeutics Korlym(米非司酮)
  • 產品簡介:Recordati SpA 的 Isturisa(Osilodrostat 磷酸鹽)
  • 產品簡介:Recordatii SpAs Signifor
  • 產品簡介:Ketoconazole for Laboratorie HRA Pharma SAS
  • 產品簡介:Laboratorie HRA Pharma SAS Metyrapone (Metyrapone)
  • 產品簡介:Lysodren of Laboratorie HRA Pharma SAS

第 5 章未滿足的需求和機會

  • CS 中未滿足的需求
  • 針對 CD 根本原因的有效治療
  • 治療重度 CS 並提高療效和安全性
  • 醫生對 CS 症狀的看法
  • 改進二級醫療機構專家轉診制度
  • 治療和緩解指南

第 6 章管道評估

  • 庫欣綜合徵管道概述
  • 主要管道代理
  • 產品簡介:Recorlev
  • 產品簡介:Relacorilant
  • 產品簡介:SPI-62
  • 管道產品-審查指定
  • 庫欣綜合徵:臨床試驗總結,II/III 期

第七章研發戰略

  • 庫欣綜合徵臨床試驗設計的趨勢
  • 庫欣綜合徵交易趨勢

第八章市場展望

  • 庫欣綜合徵銷售預測
  • 庫欣綜合徵市場預測
  • 市場驅動因素和障礙

第 9 章附錄

  • 主要調查:KOL 信息
  • 關於作者

第10章查詢

目錄
Product Code: GDHCOA007

Cushing's Syndrome is a disorder caused by the body's exposure to an excess of the hormone cortisol. Cortisol affects all tissues and organs in the body, and collectively these effects are known as CS. This disorder can be caused by exogenous sources, primarily the iatrogenic administration of glucocorticoids. Endogenous CS can result from a tumor of the adrenal glands where it produces excess cortisol, elsewhere in the body, ACTH-independent CS, or an ACTH-secreting tumor of the pituitary gland, which stimulates the adrenal glands to produce excess amounts of cortisol (CD).

This report covers 2mm (US and Germany) and provides an Excel-based forecast model for the Cushing's Syndrome market through 2030.

Key Highlights

  • Forecasts include three countries
  • Forecasts cover three time points: base year, 5-year, and 10-year

Scope

  • GlobalData's "Cushing's Syndrome - Opportunity Assessment and Forecast to 2030" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global CS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Executive Summary

  • 1.1 Executive Summary

2 Disease Overview

  • 2.1 Overview of Cushing's Syndrome

2.2 Cushing's Syndrome SWOT Analysis

  • 2.3 Classification of Cushing's Syndrome

3 Epidemiology

  • 3.1 Diagnosed Prevalent Cases of CS, 2020-2030
  • 3.2 Diagnosed Prevalent Cases of CS by Specific Type, 2020
  • 3.3 Sources and Methodology
  • 3.4 Diagnosis of Cushing's Syndrome - Treatable Population

4 Current Treatment Options

  • 4.1 Treatment Paradigm
  • 4.2 Marketed Products
  • 4.3 Product Profile: Corcept Therapeutics' Korlym (mifepristone)
  • 4.4 Product Profile: Recordati SpA's Isturisa (osilodrostat phosphate)
  • 4.5 Product Profile: Recordatii SpAs Signifor (pasireotide)
  • 4.6 Product Profile: Laboratorie HRA Pharma SAS' Ketoconazole
  • 4.7 Product Profile: Laboratorie HRA Pharma SAS' Metopirone (metyrapone)
  • 4.8 Product Profile: Laboratorie HRA Pharma SAS' Lysodren (mitotane)

5 Unmet Needs and Opportunities

  • 5.1 Unmet Needs in CS
  • 5.2 Efficacious Therapies that Target Underlying Causes of CD
  • 5.3 Therapies for Severe CS with Improved Efficacy and Safety
  • 5.4 Physician Awareness of CS Symptomatology
  • 5.5 Improved Referral Systems to Specialists in Secondary Healthcare Settings
  • 5.6 Defined Guidelines for Treatment and Remission

6 Pipeline Assessment

  • 6.1 Cushing's Syndrome Pipeline Overview
  • 6.2 Leading Pipeline Agents
  • 6.3 Product Profile: Recorlev
  • 6.4 Product Profile: Relacorilant
  • 6.5 Product Profile: SPI-62
  • 6.6 Pipeline Products - Review Designations
  • 6.7 Cushing's Syndrome: Clinical Trials Overview, Phase II/III

7 R&D Strategies

  • 7.1 Trends in Clinical Trial Design in Cushing's Syndrome
  • 7.2 Trends in Deal-Making in Cushing's Syndrome

8 Market Outlook

  • 8.1 Cushing's Syndrome Sales Forecast
  • 8.2 Cushing's Syndrome Market Forecast
  • 8.3 Market Drivers and Barriers

9 Appendix

  • 9.1 Primary Research: KOL Information
  • 9.2 About the Authors

10 Contact Us

List of Figures

List of Figures

  • Figure 1: Summary of Key Findings